Stock listing
Frankfurt:2CV ConvaTec Group PLC Aktie
German listing (Frankfurt) of ConvaTec Group PLC · home listing LSE:CTEC
Follow ConvaTec Group PLC into a list and get an email when it puts out news.
Share price · FWB:2CV
€3.16 EUR +0.06 (+1.9%)
Close on Nov 20, 2026
- Day range
- €3.06 – €3.16 EURNov 20, 2026
- Market cap
- €6.04B EURAt the close on Nov 20, 2026 · price × 1.91B shares outstanding
- 52-week range
- €2.15 – €3.16 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €1,810 EURMedian day 0 shares · 41 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:CTEC · Home | 265.80p GBX (pence) | -4.20 (-1.6%) | 6,332,697 | 268.20p | 270.40p | 262.80p | 270.00p | Close on Nov 20, 2026 |
| OTC:CNVVF | $3.218 USD | -0.122 (-3.7%) | 9,024 | $3.18 | $3.218 | $3.18 | $3.34 | Close on Nov 11, 2026 |
| OTC:CNVVY | $13.90 USD | -0.19 (-1.3%) | 3,950 | $13.91 | $13.91 | $13.90 | $14.09 | Close on Nov 20, 2026 |
| Frankfurt:2CV | €3.16 EUR | +0.06 (+1.9%) | — | €3.06 | €3.16 | €3.06 | €3.10 | Close on Nov 20, 2026 |
| Frankfurt:2CVU | €12.60 EUR | -0.20 (-1.6%) | — | €12.60 | €12.60 | €12.60 | €12.80 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:2CV · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €3.00 | +0.103 | +3.6% | €2.89 | €3.009 | €2.878 | 0 | |
| €2.897 | +0.11 | +3.9% | €2.897 | €2.897 | €2.897 | 360 | |
| €2.787 | -0.036 | -1.3% | €2.787 | €2.787 | €2.787 | 360 | |
| €2.823 | -0.068 | -2.4% | €2.823 | €2.823 | €2.823 | 0 | |
| €2.891 | -0.025 | -0.9% | €2.809 | €2.896 | €2.802 | 0 | |
| €2.916 | +0.136 | +4.9% | €2.77 | €2.943 | €2.765 | 1,552 | |
| €2.78 | +0.067 | +2.5% | €2.78 | €2.78 | €2.78 | 2,000 | |
| €2.713 | -0.078 | -2.8% | €2.713 | €2.713 | €2.713 | 4,928 | |
| €2.791 | +0.004 | +0.1% | €2.791 | €2.791 | €2.791 | 0 | |
| €2.787 | -0.109 | -3.8% | €2.787 | €2.787 | €2.787 | 8,378 | |
| €2.896 | +0.163 | +6.0% | €2.772 | €2.911 | €2.77 | 1,730 | |
| €2.733 | +0.045 | +1.7% | €2.733 | €2.733 | €2.733 | 0 | |
| €2.688 | +0.032 | +1.2% | €2.688 | €2.688 | €2.688 | 0 | |
| €2.656 | -0.103 | -3.7% | €2.656 | €2.656 | €2.656 | 0 | |
| €2.759 | -0.012 | -0.4% | €2.693 | €2.787 | €2.676 | 0 | |
| €2.771 | +0.134 | +5.1% | €2.705 | €2.803 | €2.661 | 0 | |
| €2.637 | +0.016 | +0.6% | €2.637 | €2.637 | €2.637 | 0 | |
| €2.621 | +0.02 | +0.8% | €2.621 | €2.621 | €2.621 | 0 | |
| €2.601 | -0.113 | -4.2% | €2.601 | €2.601 | €2.601 | 0 | |
| €2.714 | +0.323 | +13.5% | €2.501 | €2.722 | €2.497 | 0 | |
| €2.391 | -0.045 | -1.8% | €2.391 | €2.391 | €2.391 | 1,164 | |
| €2.436 | -0.02 | -0.8% | €2.436 | €2.436 | €2.436 | 0 | |
| €2.456 | -0.012 | -0.5% | €2.456 | €2.456 | €2.456 | 0 | |
| €2.468 | -0.097 | -3.8% | €2.468 | €2.468 | €2.468 | 0 | |
| €2.565 | +0.005 | +0.2% | €2.455 | €2.594 | €2.441 | 0 | |
| €2.56 | +0.13 | +5.3% | €2.45 | €2.58 | €2.441 | 0 | |
| €2.43 | +0.002 | +0.1% | €2.43 | €2.43 | €2.43 | 0 | |
| €2.428 | +0.067 | +2.8% | €2.428 | €2.428 | €2.428 | 0 | |
| €2.361 | -0.133 | -5.3% | €2.361 | €2.361 | €2.361 | 0 | |
| €2.494 | +0.059 | +2.4% | €2.34 | €2.511 | €2.336 | 0 | |
| €2.435 | -0.016 | -0.7% | €2.38 | €2.436 | €2.35 | 3,330 | |
| €2.451 | -0.059 | -2.4% | €2.395 | €2.463 | €2.388 | 0 | |
| €2.51 | +0.004 | +0.2% | €2.424 | €2.535 | €2.42 | 0 | |
| €2.506 | -0.016 | -0.6% | €2.405 | €2.515 | €2.398 | 0 | |
| €2.522 | +0.024 | +1.0% | €2.398 | €2.525 | €2.397 | 240 | |
| €2.498 | -0.018 | -0.7% | €2.433 | €2.499 | €2.423 | 414 | |
| €2.516 | -0.011 | -0.4% | €2.416 | €2.519 | €2.406 | 0 | |
| €2.527 | -0.034 | -1.3% | €2.42 | €2.561 | €2.42 | 0 | |
| €2.561 | +0.011 | +0.4% | €2.442 | €2.575 | €2.44 | 0 | |
| €2.55 | +0.033 | +1.3% | €2.40 | €2.554 | €2.396 | 0 | |
| €2.517 | -0.02 | -0.8% | €2.437 | €2.526 | €2.432 | 0 | |
| €2.537 | -0.004 | -0.2% | €2.475 | €2.539 | €2.465 | 0 | |
| €2.541 | -0.024 | -0.9% | €2.484 | €2.549 | €2.484 | 0 | |
| €2.565 | -0.088 | -3.3% | €2.542 | €2.574 | €2.533 | 0 | |
| €2.653 | -0.004 | -0.2% | €2.564 | €2.66 | €2.562 | 0 | |
| €2.657 | +0.076 | +2.9% | €2.556 | €2.665 | €2.518 | 750 | |
| €2.581 | -0.117 | -4.3% | €2.581 | €2.581 | €2.581 | 0 | |
| €2.698 | +0.174 | +6.9% | €2.582 | €2.698 | €2.576 | 8,570 | |
| €2.524 | -0.11 | -4.2% | €2.524 | €2.524 | €2.524 | 0 | |
| €2.634 | -0.002 | -0.1% | €2.565 | €2.666 | €2.538 | 0 | |
| €2.636 | -0.065 | -2.4% | €2.57 | €2.653 | €2.563 | 226 | |
| €2.701 | +0.148 | +5.8% | €2.534 | €2.707 | €2.522 | 0 | |
| €2.553 | -0.084 | -3.2% | €2.553 | €2.553 | €2.553 | 0 | |
| €2.637 | +0.12 | +4.8% | €2.552 | €2.638 | €2.55 | 3,998 | |
| €2.517 | -0.127 | -4.8% | €2.517 | €2.517 | €2.517 | 0 | |
| €2.644 | +0.089 | +3.5% | €2.53 | €2.655 | €2.523 | 200 | |
| €2.555 | -0.045 | -1.7% | €2.555 | €2.555 | €2.555 | 0 |
- Ticker
- Frankfurt:2CV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 18, 2026
Holding(s) in Company
Latest earnings call · Aug 4, 2026
ConvaTec Group (LSE:CTEC) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Aug 4, 2026
H1 2026 Earnings Presentation
Earnings · 42 slides
Latest news
Director updates
Nov 3, 2026
Closed €2.82 (-2.4%) on Nov 3, 2026
Chief Financial Officer succession
Nov 3, 2026
Closed €2.82 (-2.4%) on Nov 3, 2026
Total Voting Rights
Nov 2, 2026
Closed €2.89 (-0.9%) on Nov 2, 2026
Director/PDMR Shareholding
Oct 14, 2026
Closed €2.62 (+0.8%) on Oct 14, 2026
Convatec Survey Challenges Assumptions About Leakage in Ostomy Care
Oct 6, 2026
Closed €2.47 (-3.8%) on Oct 6, 2026
Convatec Expands Cure Portfolio With Launch of Cure Aqua, Bringing Greater Choice to People Who Catheterize
Sep 29, 2026
Closed €2.36 (-5.3%) on Sep 29, 2026
ConvaTec Group PLC on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 38 in the last 12 months · 169 in all · newest Nov 18, 2026 · oldest 2016
- Calls
- 5 calls with a replay · 5 with a transcript · latest Aug 4, 2026
- Decks
- 33 decks · latest Aug 4, 2026
Where ConvaTec Group PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:CTEC · Home listing | LSE | United Kingdom | GBX |
| OTC:CNVVF | OTC | United States | USD |
| OTC:CNVVY | OTC | United States | USD |
| LS Exchange:A2AUD3 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2AUD3 | Lang & Schwarz | Germany | EUR |
| gettex:2CV | gettex | Germany | EUR |
| BX Swiss:2CV | BX Swiss | Switzerland | CHF |
| Aquis:CTECL | Aquis | United Kingdom | GBX |
| BIVA:CTEC1N | BIVA | Mexico | MXN |
| BMV:CTEC1N | BMV | Mexico | MXN |
| Dusseldorf:2CV | Dusseldorf | Germany | EUR |
| Dusseldorf:2CVU | Dusseldorf | Germany | EUR |
| Frankfurt:2CV · This page | Frankfurt | Germany | EUR |
| Frankfurt:2CVU | Frankfurt | Germany | EUR |
| Hanover:2CV | Hanover | Germany | EUR |
| Munich:2CV | Munich | Germany | EUR |
| Stuttgart:2CV | Stuttgart | Germany | EUR |
| Tradegate:2CV | Tradegate | Germany | EUR |
| Turquoise:CTECL | Turquoise | United Kingdom | GBX |
Valuation
P/E 37.9× against a median of 25.6×: 8th lowest of 11 Medical devices & supplies companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- £6.34B GBP
- P/E
- 37.9×
- EV/sales
- 3.4×
- EV/EBITDA
- 15.2×
- Price/book
- 4.6×
- Gross margin
- 56.2%
- Operating margin
- 13.0%
- Net margin
- 7.2%
- Debt to equity
- 1.2×
- Beta
- No index for this market yet
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ConvaTec Group PLC · LSE:CTEC | US$6.64B | US$8.29B | 37.9× | 3.4× | 15.2× | 4.6× | 7.2% | 1.2× | n/a |
| Insulet Corporation · NASDAQ:PODD | US$9.24B | US$9.62B | 21.5× | 3.0× | 13.9× | 5.8× | 13.5% | 0.6× | 0.53 |
| Globus Medical, Inc. · NYSE:GMED | US$7.48B | US$7.07B | 13.4× | 2.3× | 7.4× | 1.6× | 17.8% | 0.0× | 0.89 |
| Getinge AB Class B · OMXSTO:GETI_B | US$6.88B | US$7.67B | 24.9× | 2.3× | 11.2× | 2.1× | 8.2% | 0.3× | n/a |
| Teleflex Incorporated · NYSE:TFX | US$6.85B | US$8.04B | 22.5× | 3.6× | 20.1× | 2.0× | 13.5% | 0.5× | 0.50 |
| Ypsomed Holding AG · SIX:YPSN | US$6.80B | US$6.76B | 25.7× | 7.8× | 17.3× | 7.2× | 30.4% | 0.0× | n/a |
| Cochlear Limited · ASX:COH | US$6.49B | US$6.51B | 66.6× | 4.2× | 24.2× | 5.6× | 6.3% | 0.1× | n/a |
| APT Medical Inc. Class A · SSE:688617 | US$5.98B | US$5.72B | 39.3× | 12.4× | n/a | 11.8× | 33.0% | 0.0× | n/a |
| Haemonetics Corporation · NYSE:HAE | US$5.47B | US$6.35B | 52.7× | 4.6× | 22.1× | 6.1× | 7.5% | 1.3× | 0.27 |
| Merit Medical Systems, Inc. · NASDAQ:MMSI | US$5.05B | US$5.29B | 31.6× | 3.3× | 15.4× | 2.9× | 9.9% | 0.4× | 0.49 |
| LivaNova PLC · NASDAQ:LIVN | US$5.00B | US$4.73B | 25.5× | 3.1× | 21.6× | 3.6× | 13.0% | 0.2× | 1.02 |
| Median of the others | US$6.65B | US$6.63B | 25.6× | 3.4× | 17.3× | 4.6× | 13.2% | 0.3× | 0.52 |
Forecasts
Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 306.48 GBX · Analysts' mean
- EPS, year to Dec 2026
- 0.20 · 19 analysts
- Revenue, year to Dec 2026
- 2.55B · 18 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jonny Mason | Chief Executive Officer |
| Fiona Ryder | Chief Financial Officer |
| Bruno Pinheiro | President, Ostomy Care |
| Kjersti Grimsrud | President, Infusion Care |
| James Kerton | General Counsel & Company Secretary |
| Dave Ubachs | Chief Digital & Information Officer |
| Emma Rose | Chief People Officer |
| Jens Viebke | |
| Neal Carty | Chief Science & Innovation Officer |
| Peter Jarvis | Chief Operations Officer |
Board
| Director | Role |
|---|---|
| Brian May | Chair |
| John McAdam | Chairman |
| Tobias Hestler | Independent Non-Executive Director |
| Heather Mason | Independent Non-Executive Director |
| Kim Lody | Independent Non-Executive Director |
| Kimberly Lody | |
| Margaret Ewing | Independent Non-Executive Director |
| Sharon O'Keefe | Independent Non-Executive Director |
Events
- Next results
- Feb 23, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| ConvaTec Group (LSE:CTEC) Q2 2026 Earnings Call | Tue, Aug 04, 2026 | Replay |
| ConvaTec Group (LSE:CTEC) Q2 2025 Earnings Call | Tue, Jul 29, 2025 · 4:45 AM ET | Replay |
| ConvaTec Group (LSE:CTEC) Q4 2024 Earnings Call | Wed, Feb 26, 2025 · 5:00 AM ET | Replay |
| ConvaTec Group (LSE:CTEC) Q2 2024 Earnings Call | Tue, Jul 30, 2024 · 4:00 AM ET | Replay |
| ConvaTec Group (LSE:CTEC) Q4 2023 Earnings Call | Wed, Mar 06, 2024 · 4:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Jul 29, 2025 · After close | −5.5% |
| Quarter to Mar 31, 2025 | May 22, 2025 | +3.7% |
| Q4 2024 | Feb 26, 2025 | +5.2% |
| Q4 2023 | Mar 6, 2024 | +9.2% |
| Quarter to Sep 30, 2023 | Nov 14, 2023 | +8.1% |
| Q2 2023 | Aug 2, 2023 · Before open | +6.3% |
| Q1 2023 | May 18, 2023 | +5.1% |
| Q4 2022 | Mar 9, 2023 · Before open | −1.2% |
| Q3 2022 | Nov 10, 2022 | +6.0% |
| Q2 2022 | Aug 4, 2022 · Before open | +6.8% |
All 16 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2022 | May 12, 2022 | +8.3% |
| Q4 2021 | Mar 8, 2022 · Before open | +4.2% |
| Q3 2021 | Oct 29, 2021 | +7.5% |
| Q2 2021 | Jul 30, 2021 | −12.8% |
| Q1 2021 | Apr 29, 2021 | +5.1% |
| Q4 2020 | Mar 5, 2021 | +0.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2026 Earnings Presentation | Earnings | 42 slides | Aug 4, 2026 |
| Corporate Update (May 2026) | Corporate update | 8 slides | May 21, 2026 |
| Investor Day (April 2026) | Investor day | 101 slides | April 2026 |
| FY2025 Earnings Presentation | Earnings | 42 slides | Feb 24, 2026 |
| 10M 2025 Earnings Presentation | Earnings | 9 slides | Nov 13, 2025 |
| H1 2025 Earnings Presentation | Earnings | 32 slides | Jul 29, 2025 |
| Shareholder Meeting (May 2025) | Shareholder meeting | 11 slides | May 22, 2025 |
| FY2024 Earnings Presentation | Earnings | 40 slides | Feb 26, 2025 |
| FY2024 Earnings Presentation | Earnings | 8 slides | November 2024 |
| H1 2024 Earnings Presentation | Earnings | 34 slides | Jul 30, 2024 |
All 33 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2023 Earnings Presentation | Earnings | 33 slides | Mar 6, 2024 |
| H1 2023 Earnings Presentation | Earnings | 36 slides | Aug 2, 2023 |
| FY2022 Earnings Presentation | Earnings | 33 slides | Mar 9, 2023 |
| Investor Day (November 2022) | Investor day | 96 slides | Nov 17, 2022 |
| H1 2022 Earnings Presentation | Earnings | 25 slides | Aug 4, 2022 |
| FY2021 Earnings Presentation | Earnings | 33 slides | Mar 8, 2022 |
| H1 2021 Earnings Presentation | Earnings | 24 slides | Jul 30, 2021 |
| FY2020 Earnings Presentation | Earnings | 33 slides | Mar 5, 2021 |
| H1 2020 Earnings Presentation | Earnings | 28 slides | Aug 6, 2020 |
| Fact Sheet (July 2020) | Fact sheet | 1 slide | Jul 30, 2020 |
| FY2019 Earnings Presentation | Earnings | 35 slides | Feb 28, 2020 |
| H1 2019 Earnings Presentation | Earnings | 35 slides | Aug 1, 2019 |
| Q1 2019 Earnings Presentation | Earnings | 15 slides | May 3, 2019 |
| Fact Sheet (March 2019) | Fact sheet | 1 slide | March 2019 |
| FY2018 Earnings Presentation | Earnings | 44 slides | Feb 14, 2019 |
| Q3 2018 Earnings Presentation | Earnings | 14 slides | Oct 15, 2018 |
| H1 2018 Earnings Presentation | Earnings | 28 slides | Aug 2, 2018 |
| Q1 2018 Earnings Presentation | Earnings | 15 slides | May 2, 2018 |
| FY2017 Earnings Presentation | Earnings | 38 slides | Feb 15, 2018 |
| Q3 2017 Earnings Presentation | Earnings | 17 slides | Oct 16, 2017 |
| H1 2017 Earnings Presentation | Earnings | 29 slides | Aug 3, 2017 |
| Q1 2017 Earnings Presentation | Earnings | 14 slides | May 4, 2017 |
| FY2016 Earnings Presentation | Earnings | 37 slides | Mar 2, 2017 |
Financings
| Raise | Date |
|---|---|
| 5.300% senior notes due 2035 Update: US$500M Use of proceeds: Refinance existing debt, including prepaying the term loan facility in full and part of the revolving credit facility, and general corporate purposes | Oct 2, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.44B | 2.29B | 2.14B | 2.07B | 2.04B | 1.89B | 1.83B | 1.83B | 1.76B | 1.69B |
| Cost of revenue | 1.07B | 1.00B | 941.8M | 968.6M | 915.2M | 874.2M | 871.6M | 855.0M | 812.7M | 778.4M |
| Gross profit | 1.37B | 1.28B | 1.20B | 1.10B | 1.12B | 1.02B | 955.6M | 977.1M | 951.9M | 909.9M |
| Research and development | 111.0M | 112.0M | 110.0M | 92.0M | 94.5M | 82.4M | 54.8M | 49.9M | 57.8M | 53.0M |
| Selling, general and administrative | 206.0M | 195.0M | 200.4M | 204.7M | 258.7M | 251.4M | 230.2M | 231.7M | 253.3M | 313.2M |
| Operating income | 316.0M | 325.0M | 262.7M | 207.3M | 203.6M | 211.0M | 214.4M | 280.8M | 281.1M | 203.7M |
| Depreciation and amortization | 228.7M | 220.8M | 214.8M | 209.2M | 210.6M | 197.7M | 209.8M | 190.0M | 179.4M | 168.5M |
| EBITDA | 544.7M | 545.8M | 477.5M | 416.5M | 414.2M | 408.7M | 424.2M | 470.8M | 460.5M | 372.2M |
| Interest expense | 71.0M | 83.0M | 80.7M | 57.6M | 44.3M | 44.1M | 73.6M | 65.2M | 58.4M | 271.4M |
| Income before tax | 230.0M | 246.0M | 167.4M | 81.9M | 151.3M | 174.7M | 18.9M | 201.2M | 164.0M | -125.8M |
| Income tax | 55.0M | 55.0M | 37.1M | 19.0M | 33.7M | 62.2M | 9.10M | -20.4M | 5.60M | 77.0M |
| Net income | 175.0M | 191.0M | 130.3M | 62.9M | 117.6M | 112.5M | 9.80M | 221.6M | 158.4M | -202.8M |
| Earnings per share, basic | 0.09 | 0.09 | 0.06 | 0.03 | 0.06 | 0.06 | 0.00 | 0.11 | 0.08 | -0.10 |
| Earnings per share, diluted | 0.09 | 0.09 | 0.06 | 0.03 | 0.06 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 68.0M | 65.0M | 98.0M | 143.8M | 463.4M | 565.4M | 385.8M | 315.6M | 289.3M | 264.1M |
| Short-term investments | 700.0K | 2.00M | 1.90M | 2.60M | ||||||
| Receivables | 439.2M | 301.0M | 269.8M | 285.1M | 250.6M | 245.2M | 247.1M | 245.6M | 256.4M | 233.7M |
| Inventory | 416.0M | 349.0M | 396.1M | 336.9M | 308.8M | 297.1M | 281.8M | 303.3M | 284.5M | 247.5M |
| Current assets | 940.0M | 793.0M | 870.0M | 889.3M | 1.11B | 1.18B | 968.3M | 903.2M | 875.1M | 770.8M |
| Property, plant and equipment | 673.0M | 503.0M | 473.8M | 400.4M | 366.7M | 438.0M | 406.1M | 330.7M | 334.0M | 264.8M |
| Goodwill | 1.35B | 1.29B | 1.30B | 1.22B | 1.16B | 1.10B | 1.07B | 1.04B | 1.07B | 921.0M |
| Total assets | 3.78B | 3.52B | 3.71B | 3.59B | 3.67B | 3.77B | 3.61B | 3.66B | 3.80B | 3.51B |
| Accounts payable | 493.0M | 382.0M | 388.7M | 346.6M | 342.5M | 98.2M | 90.5M | 89.1M | 122.0M | 111.6M |
| Current liabilities | 616.0M | 511.0M | 536.4M | 533.1M | 569.2M | 513.2M | 397.3M | 330.9M | 338.5M | 300.0M |
| Long-term debt | 1.40B | 1.12B | 1.23B | 1.21B | 1.20B | 1.37B | 1.45B | 1.56B | 1.74B | 1.74B |
| Total debt | 1.40B | 1.12B | 1.23B | 1.21B | 1.34B | 1.55B | 1.57B | 1.64B | 1.82B | 1.78B |
| Total liabilities | 2.26B | 1.83B | 2.02B | 1.98B | 1.98B | 2.10B | 2.05B | 2.04B | 2.28B | 2.27B |
| Shareholders' equity | 1.52B | 1.69B | 1.69B | 1.61B | 1.69B | 1.67B | 1.56B | 1.62B | 1.52B | 1.25B |
| Shares outstanding | 2.03B | 2.06B | 2.05B | 2.04B | 2.03B | 2.01B | 1.98B | 1.96B | 1.95B | 1.95B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 470.0M | 397.0M | 367.4M | 281.7M | 305.9M | 399.5M | 401.8M | 352.0M | 306.6M | 74.9M |
| Capital spending | -137.8M | -122.1M | -129.2M | -144.2M | -94.1M | -86.2M | -61.4M | -72.1M | -82.7M | -66.5M |
| Free cash flow | 342.0M | 274.1M | 238.2M | 137.5M | 211.8M | 313.3M | 340.4M | 279.9M | 223.9M | 8.40M |
| Cash from investing | -208.0M | -161.0M | -285.7M | -348.3M | -206.5M | -56.3M | -72.8M | -80.9M | -182.6M | -63.7M |
| Cash from financing | -258.0M | -264.0M | -124.0M | -237.1M | -199.9M | -162.1M | -252.5M | -229.4M | -119.3M | 4.50M |
| Dividends paid | -140.0M | -130.0M | -110.7M | -88.1M | -85.8M | -62.9M | -79.9M | -74.9M | -26.3M | -26.3M |
| Share buybacks | -326.0M | -11.0M | 0 | 0 | -5.60M | -14.0M | 0 | -9.60M | 1.76B | |
| Change in cash | 4.00M | -28.0M | -42.3M | -303.7M | -100.5M | 179.6M | 70.2M | 26.3M | 25.2M | -8.90M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Transaction in Own Shares | Nov 16, 2026 | Treasury share status | London Stock Exchange |
| Transaction in Own Shares | Nov 9, 2026 | Treasury share status | London Stock Exchange |
| Transaction in Own Shares | Nov 2, 2026 | Treasury share status | London Stock Exchange |
Cap table
Built by 6ix from ConvaTec Group PLC’s releases
- Common shares
- 1,908,856,496
- Fully diluted
- 1,908,856,496
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,908,856,496 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,908,856,496 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Brian May Other companies: Ferguson Enterprises Inc. (Independent Director · Since at least Dec 5, 2024) | Chair · Since at least May 22, 2025 |
| Tobias Hestler Other companies: Hikma Pharmaceuticals PLC (Independent Non-Executive Director · Since at least Aug 6, 2026) | Independent Non-Executive Director · Since at least Aug 6, 2026 |
| Andrew Dahlinghaus | Chief Operating Officer · Dec 8, 2025 – Nov 5, 2026 · Past |
| Bruno Pinheiro | President, Ostomy Care · Since at least Oct 6, 2026 |
| Dave Ubachs | Chief Digital & Information Officer · Since at least Nov 4, 2026 |
| Emma Rose | Chief People Officer · Since at least Nov 4, 2026 |
| Fiona Ryder | Chief Financial Officer · Since at least Aug 4, 2026 |
| Heather Mason | Independent Non-Executive Director · Since at least May 22, 2025 |
| James Kerton | General Counsel & Company Secretary · Since at least Oct 14, 2026 |
| Jens Viebke | Officer · Since at least Oct 14, 2026 |
All 19 people
| Person | Seat |
|---|---|
| John McAdam | Chairman · Since at least Jul 15, 2026 |
| Jonny Mason | Chief Executive Officer · Since at least Aug 4, 2026 |
| Kimberly Lody | Director · Since at least Nov 5, 2026 |
| Kim Lody | Independent Non-Executive Director · Since at least May 22, 2025 |
| Kjersti Grimsrud | President, Infusion Care · Since at least Nov 4, 2026 |
| Margaret Ewing | Independent Non-Executive Director · Since at least Jul 15, 2026 |
| Neal Carty | Chief Science & Innovation Officer · Since at least Jun 4, 2026 |
| Peter Jarvis | Chief Operations Officer · Since at least Nov 4, 2026 |
| Sharon O'Keefe | Independent Non-Executive Director · Since at least May 22, 2025 |
Log in to ask 6ix AI your own questions about ConvaTec Group PLC.